Driver Clocks And Longevity — Dissecting True Functional “Drivers” Of Aging Phenotypes — Dr. Daniel Ives Ph.D., Founder and CEO — Shift Bioscience Ltd.
Dr. Daniel Ives, Ph.D. is Founder and CEO of Shift Bioscience Ltd. (https://shiftbioscience.com), a biotech company making drugs for cellular rejuvenation in humans through the application of machine-learning ‘driver’ clocks to cellular reprogramming, and is the scientific founder who first discovered the gene shifting targets upon which the Shift drug discovery platform is based.
Dr. Ives graduated from Imperial College with a degree in biochemistry and gained his PhD in 2013 working at the MRC Mitochondrial Biology Unit in Cambridge. He carried out his post-doctoral studies under Ian Holt at the National Institute of Medical Research in Mill Hill, now part of the Crick Institute, pursuing damage-removal strategies for mitochondrial DNA mutations.
In 2016 Dr. Ives left the Crick Institute and founded Shift Bioscience to commercialize mitochondrial targeted drugs for age linked diseases, incorporating novel ageing biomarkers technologies, CRISPR screens, and other tools to dissect true functional ‘drivers’ of ageing phenotypes.
Comments are closed.